UCYCLYD PROTOCOL UP 1204-003: A PHASE 2, OPEN-LABEL, SWITCH-OVER, DOSE-ESCALATIO

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项临床试验将评估研究药物GT4P与丁苯在尿素循环障碍(UCDS)患者中的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This clinical trial will evaluate the safety and tolerability of an investigational drug, GT4P, compared to Buphenyl in patients with urea cycle disorders (UCDs).